CompanyGraph
Hua Medicine Ltd.
2552 · HKEX · China
Price data from its HUMDF listing on OTC, quoted in USD
huamedicine.comFinancials as of FY2025
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 2.42: grey zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
3.34BHKD425.31M · vs all stocks (USD)
Trailing P/E
2.02xRevenue (TTM)
573.67MCNY73.14M · vs all stocks (USD)
Profit Margin
224.44%Beta
0.8020xvs all stocks
52-Week Change
-33.38%vs all stocks
Market Capitalization
3.34BHKD425.31M · vs all stocks (USD)
Enterprise Value
2.08BHKD265.64M · vs all stocks (USD)
Trailing P/E
2.02xForward P/E
-5.51xPrice to Sales (TTM)
5.24xPrice to Book (MRQ)
2.20xEnterprise to Revenue
3.63xEnterprise to EBITDA
-13.58xProfit Margin
224.44%Operating Margin
-28.89%Return on Assets (TTM)
-6.04%Return on Equity (TTM)
254.05%Revenue (TTM)
573.67MCNY73.14M · vs all stocks (USD)
Revenue per Share (TTM)
0.4990CNYUpdated Aug 19, 2026Quarterly Revenue Growth
79.80%Gross Profit (TTM)
326.27MCNY41.60M · vs all stocks (USD)
EBITDA (TTM)
-153.38MCNY-19.55M · vs all stocks (USD)
Net Income (TTM)
1.29BCNY164.15M · vs all stocks (USD)
Operating Cash Flow (TTM)
-60.69MCNY-7.74M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-138.55MCNY-17.66M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
492.93MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
212.58MCNYFY2025 · Dec 31, 2025Gross Profit
280.36MCNYFY2025 · Dec 31, 2025Operating Income
-135.95MCNY-20.16M · vs all stocks (USD)
Pre-tax Income
1.11BCNYFY2025 · Dec 31, 2025Income Tax Expense
0.00CNYFY2025 · Dec 31, 2025Net Income
1.11BCNYFY2025 · Dec 31, 2025EBIT
1.11BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-96.53MCNYFY2025 · Dec 31, 2025Research & Development
145.32MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
279.92MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
11.49MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.15MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.12CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.10CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
987.82MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
987.82MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.11BCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-138.62MCNYFY2025 · Dec 31, 2025Free Cash Flow
-146.17MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.09BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.11BCNYFY2025 · Dec 31, 2025Stock-based Compensation
12.19MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-1.25BCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-21.85MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
13.91MCNYFY2025 · Dec 31, 2025Capital Expenditures
-7.55MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00CNYFY2025 · Dec 31, 2025Other Investing Activity
-2.25MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-9.80MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
112.43MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-98.28MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
36.62MCNYFY2025 · Dec 31, 2025Shares Outstanding
996.52MSharesUpdated Aug 19, 2026Float Shares
660.56MSharesUpdated Aug 19, 2026% Held by Insiders
13.25%vs all stocks
% Held by Institutions
22.62%vs all stocks
Total Cash (MRQ)
1.27BCNY162.06M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.10CNYUpdated Aug 19, 2026Total Debt (MRQ)
351.08MCNY44.76M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2997xCurrent Ratio (MRQ)
6.17xBook Value per Share (MRQ)
1.18CNYUpdated Aug 19, 2026Total Assets
1.47BCNY217.96M · vs all stocks (USD)
Total Current Assets
1.30BCNYFY2025 · Dec 31, 2025Total Liabilities
463.28MCNYFY2025 · Dec 31, 2025Total Non-current Assets
173.31MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
253.01MCNYFY2025 · Dec 31, 2025Total Current Liabilities
210.27MCNYFY2025 · Dec 31, 2025Cash
1.09BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.09BCNYFY2025 · Dec 31, 2025Accounts Receivable
74.83MCNYFY2025 · Dec 31, 2025Inventory
121.67MCNYFY2025 · Dec 31, 2025Accounts Payable
81.65MCNYFY2025 · Dec 31, 2025Short-term Debt
48.66MCNYFY2025 · Dec 31, 2025Long-term Debt
253.01MCNYFY2025 · Dec 31, 2025Common Stock (Book)
7.22MCNYFY2025 · Dec 31, 2025Retained Earnings
-5.25BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.01BCNY149.26M · vs all stocks (USD)
Treasury Stock
411.00KCNYFY2025 · Dec 31, 202552-Week Low
1.97HKDUpdated Aug 19, 202652-Week High
4.95HKDUpdated Aug 19, 202652-Week Change
-33.38%vs all stocks
Beta
0.8020xvs all stocks
50-Day MA
2.41HKDUpdated Aug 19, 2026200-Day MA
3.03HKDUpdated Aug 19, 2026Avg 10-Day Volume
1.62MSharesUpdated Aug 19, 2026Avg 30-Day Volume
2.17MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
1.28CNYUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 164,149,943.54Operating Cash Flow (USD, TTM): -7,737,511.781
Financial Health
Altman Z-Score 2.42: grey zoneSignificant
Altman Z-Score: 2.42
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Jiangsu Canopus Wisdom MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Jiaoda Onlly Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kehua Bio-Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Qinghai Spring Medicinal Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tenax Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nanhua Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eupraxia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Elite Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abclon Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Zhejiang Meishuo Electric Co. Ltd.
1 interpretationMinimal Tax and Interest Drag
Shandong Keyuan Pharmaceutical Co., Ltd.
1 interpretationMinimal Tax and Interest Drag
VM Inc.
1 interpretationMinimal Tax and Interest Drag